Author Archives: Marisa Wexler MS

Enrollment Complete for RejuvenAir Metered Cryospray Trial

Enrollment is now concluded in a clinical trial evaluating the mechanism of action of RejuvenAir Metered Cryospray, an investigational treatment for chronic bronchitis, the most common form of chronic obstructive pulmonary disease (COPD). Chronic bronchitis is long-term inflammation of the airways, characterized by coughing and excessive mucus production.

Smiths Medical Launches Vibratory PEP Device for Lung Disorders

Smiths Medical has launched a medical device designed to help people with chronic obstructive pulmonary disease (COPD) and other respiratory diseases to clear secretions from their lungs and breathe better. “The introduction of the acapella choice blue therapy system enhances the quality of life for those living with…

FDA Approval Sought for New Generic Version of Advair Diskus

Lannett is seeking the approval of a generic form of Advair Diskus (fluticasone-salmeterol powder) in the U.S. Such an approval would be expected to provide a less-expensive alternative to the inhalation treatment that generated about $3 billion in total U.S. sales for the 12 months ending in February 2021,…

Trixeo Aerosphere Approved in Scotland as COPD Maintenance Therapy

The Scottish Medicines Consortium (SMC) has approved AstraZeneca‘s triple combination therapy Trixeo Aerosphere as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The approval specifically covers adults with moderate to severe disease who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a…

FDA Gives Green Light to Clinical Trial of Zofin

The U.S. Food and Drug Administration (FDA) has granted Organicell Regenerative Medicine permission to begin a clinical trial testing the company’s lead product, Zofin, in people with chronic obstructive pulmonary disease (COPD). The approved trial design will be a double-blinded, placebo-controlled, phase 1/2 trial to assess the…

New Therapeutic Target for COPD Identified in Study

Inhibiting a protein called lymphotoxin beta receptor (LTβR) could be an effective therapeutic strategy for chronic obstructive pulmonary disease (COPD), new research suggests. The findings were published in Nature, in the study “Inhibition of LTβR signalling activates WNT-induced regeneration in lung.” COPD is characterized by the…